SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on December 27, 2007. The registrant is a Colorado-based biopharmaceutical company focused on developing diagnostic tests. The filing serves as a current report to disclose a material event regarding the company's product development pipeline.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a regulatory milestone rather than a financial statement.
Material Changes and Events
- Regulation FD Disclosure (Item 7.01): The company issued a press release outlining steps to obtain FDA 510(k) clearance for AppyScore.
- Product Focus: AppyScore is described as the first blood-based screen/triage test for human appendicitis.
- Exhibit 99.1: The full text of the press release is included as an exhibit to this filing.
Guidance, Outlook, and Risks
The filing indicates a strategic focus on advancing AppyScore through the FDA regulatory process. No specific financial guidance, management commentary on future earnings, or explicit risk factors are detailed within the body of this specific 8-K form, other than the inherent regulatory uncertainty implied by the pursuit of 510(k) clearance.
Key Facts for Investor Verification
- Verify the status of the FDA 510(k) clearance application for AppyScore as of the filing date.
- Review the attached press release (Exhibit 99.1) for specific timelines and clinical data supporting the 510(k) submission.
- Confirm the company's cash runway and funding status, as this filing does not disclose current liquidity levels.
- Note the discrepancy between the request metadata (Riot Platforms) and the actual filing content (AspenBio Pharma); this summary reflects the actual document provided.